Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methylprednisolone acetate + lidocaine + diclofenac sodium
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intralesional
01
Overview
This experimental treatment regimen, evaluated by the Universidad Autonoma de Nuevo Leon for anserine bursitis, consists of a local infiltration of methylprednisolone acetate and lidocaine (Xylocaine) in conjunction with a 10-day course of oral diclofenac sodium. Methylprednisolone acetate is a synthetic corticosteroid that acts as a glucocorticoid receptor agonist, exerting potent anti-inflammatory and immunosuppressive effects. Lidocaine is a local anesthetic that blocks voltage-gated sodium channels, providing immediate symptomatic relief at the site of infiltration. Diclofenac sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing the production of pro-inflammatory prostaglandins. This multi-modal approach targets both local and systemic inflammatory pathways to treat pes anserine bursitis.
- Brand names
- Xylocaine
- Other names
- Methylprednisolone Infiltration in Anserine BursitisMethylprednisolone infiltration in anserine bursitis treatment
02
Targets
GR (Glucocorticoid receptor)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on methylprednisolone acetate + lidocaine + diclofenac sodium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methylprednisolone acetate + lidocaine + diclofenac sodium.